Combining cohort analysis and monitoring of HIV early-warning indicators of drug resistance to assess antiretroviral therapy services in Vietnam

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 4, 2012, Pages

  Do, Thi Nhan ^a   Nguyen, Thi Minh Thu ^b   Do, Mai Hoa ^c   Masaya, Kato ^b   Dang, Thi Bich ^d   Pham, Thuy Linh ^c   Yoshikawa, Kayoko ^e   Cao, Thi Than Thuy ^d   Nguyen, Thi Thuy Van ^b   Bui, Duc Duong ^a   Nguyen, Van Kinh ^d   Nguyen, Thanh Long ^a   Fujita, Masami ^b  

^a MINISTRY OF HEALTH   (Canada)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c HANOI UNIVERSITY OF PUBLIC HEALTH   (Viet Nam)

^d MINISTRY OF HEALTH   (Viet Nam)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL RESISTANCE; BIOLOGICAL MONITORING; COHORT ANALYSIS; FOLLOW UP; GEOGRAPHY; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; VETERAN; WORLD HEALTH ORGANIZATION;

ADULT; AMBULATORY CARE FACILITIES; ANTI-RETROVIRAL AGENTS; CHILD; COHORT STUDIES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP; NATIONAL HEALTH PROGRAMS; ODDS RATIO; PATIENT COMPLIANCE; POPULATION SURVEILLANCE; VIETNAM; WORLD HEALTH ORGANIZATION;

EID: 84860352459     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir1045     Document Type: Review

References (28)

1. Vietnam Authority of HIV/AIDS Control, Ministry of Health. Vietnam HIV/AIDS estimates and projections 2007-2012. Hanoi, Vietnam: Family Health International, 2009.
2. Socialist Republic of Vietnam. Vietnam country progress report 2010 on the Declaration of Commitment on HIV/AIDS, adopted at the 26th United Nations General Assembly special session in 2001 (UNGASS report 2010). Hanoi, Vietnam: Lotus communication, 2010.
3. World Health Organization. Patient monitoring guidelines for HIV care and antiretroviral therapy (ART). Geneva, Switzerland: World Health Organization, 2006.
4. Joint United Nations Programme on HIV/AIDS (UNAIDS). Monitoring the Declaration of Commitment on HIV/AIDS: guidelines on construction of core indicators: 2010 reporting. Geneva, Switzerland: UNAIDS, 2009.
5. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13(Suppl 2):1-13. (Pubitemid 352019085)
6. World Health Organization. HIV drug resistance early warning indicators: World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites. April 2010 update. Geneva, Switzerland: World Health Organization, 2010.
7. Vietnam Authority of HIV/AIDS Control, Ministry of Health. Report on data collection of antiretroviral therapy (ART) cohort outcomes and pilot of HIV drug resistance early warning indicators. Hanoi, Vietnam, 2009.
8. Chasombat S, McConnell MS, Siangphoe U, et al. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr 2009; 50:506-12.
9. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15(Suppl 1):1-15.
10. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.
11. Hedt BL, Wadonda-Kabondo N, Makombe S, et al. Early warning indicators for HIV drug resistance in Malawi. Antivir Ther 2008; 13(Suppl 2):69-75. (Pubitemid 352019091)
12. Minister of Health. Antiretroviral treatment protocol for people living with HIV/AIDS (Decision No. 2051/QD-BYT). Hanoi, 2006.
13. Tassie JM, Baijal P, Vitoria MA, Alisalad A, Crowley SP, Souteyrand Y. Trends in retention on antiretroviral therapy in national programs in low-income and middle-income countries. J Acquir Immune Defic Syndr 2010; 54:437-41.
14. World Health Organization, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2009. Geneva, Switzerland: World Health Organization. 2009.
15. Family Health International. Results of the program evaluation of patients initiating antiretroviral therapy in two health facilities in Ho Chi Minh City, Vietnam. Hanoi, Vietnam: FHI Viet Nam, 2010.
16. Messiah A, Navaline H, Davis-Vogel A, Tobin-Fiore D, Metzger D. Sociodemographic and behavioral characteristics associated with timeliness and retention in a 6-month follow-up study of high-risk injection drug users. Am J Epidemiol 2003; 157:930-9. (Pubitemid 36555053)
17. Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 2008; 300:550-4.
18. Wisaksana R, Indrati AK, Fibriani A, et al. Response to first-line antiretroviral treatment among human immunodeficiency virus-infected patients with and without a history of injecting drug use in Indonesia. Addiction 2010; 105:1055-61.
19. Chan AC, Palepu A, Guh DP, et al. HIV-positive injection drug users who leave the hospital against medical advice: the mitigating role of methadone and social support. J Acquir Immune Defic Syndr 2004; 35:56-9. (Pubitemid 38044783)
20. Ioannidis JP, Bassett R, Hughes MD, Volberding PA, Sacks HS, Lau J. Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:22-30.
21. Lebouche B, Yazdanpanah Y, Gerard Y, et al. Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998. HIV Med 2006; 7:140-5. (Pubitemid 43337592)
22. Mocroft A, Kirk O, Aldins P, et al. Loss to follow-up in an international, multicentre observational study. HIV Med 2008; 9:261-9. (Pubitemid 351517272)
23. Jordan MR, La H, Nguyen HD, et al. Correlates of HIV-1 viral suppression in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam. Int J STD AIDS 2009; 20:418-22.
24. Massaquoi M, Zachariah R, Manzi M, et al. Patient retention and attrition on antiretroviral treatment at district level in rural Malawi. Trans R Soc Trop Med Hyg 2009; 103:594-600.
25. Forster M, Bailey C, Brinkhof MW, et al. Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ 2008; 86:939-47.
26. Farley J, Hines S, Musk A, Ferrus S, Tepper V. Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. J Acquir Immune Defic Syndr 2003; 33:211-18. (Pubitemid 36793158)
27. Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Correlates of HIV antiretroviral adherence in persons with serious mental illness. AIDS Care 2004; 16:501-6. (Pubitemid 38651066)
28. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13(Suppl 2):15-23. (Pubitemid 352019086)